title: Gemcitabine Plus Nab-Paclitaxel as Second-Line and Beyond Treatment for Metastatic Pancreatic Cancer: a Single Institution Retrospective Analysis.
abstract: Metastatic pancreatic cancer still represent one of the most deadly disease for which there are few therapeutic options, especially in second line and beyond setting. Nabpaclitaxel plus gemcitabine activity was demonstrated in first line setting, but there are no clear evidence suggesting its use after that. We report a retrospective data analysis of 23 patients who received nab-paclitaxel plus gemcitabine after first line treatment at our Oncology Department. We observed a significant clinical benefit (43,5%) with a median overall survival of 5 months. In addition, manageable side effects were reported. Our data, despite the small sample, seem to indicate that nab- paclitaxel plus gemcitabine is an active and well tolerated regimen even in pretreated patients.
authors.forename: Paola
authors.initials: P
authors.lastname: Bertocchi
authors.forename: Chiara
authors.initials: C
authors.lastname: Abeni
authors.forename: Fausto
authors.initials: F
authors.lastname: Meriggi
authors.forename: Luigina
authors.initials: L
authors.lastname: Rota
authors.forename: Anna
authors.initials: A
authors.lastname: Rizzi
authors.forename: Brunella
authors.initials: B
authors.lastname: Di Biasi
authors.forename: Francesca
authors.initials: F
authors.lastname: Aroldi
authors.forename: Chiara
authors.initials: C
authors.lastname: Ogliosi
authors.forename: Giordano
authors.initials: G
authors.lastname: Savelli
authors.forename: Edoardo
authors.initials: E
authors.lastname: Rosso
authors.affiliation: Medical Oncology, Fondazione Poliambulanza, Via Bissolati 57,25124,Brescia, Italy. azaniboni@alice.it.
authors.forename: Alberto
authors.initials: A
authors.lastname: Zaniboni
mesh_terms: D000368:Aged; D000418:Albumins / Q000627:therapeutic use*; D000964:Antimetabolites, Antineoplastic / Q000627:therapeutic use*; D003841:Deoxycytidine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009362:Neoplasm Metastasis; D017239:Paclitaxel / Q000627:therapeutic use*; D010190:Pancreatic Neoplasms / Q000188:drug therapy* / Q000473:pathology; D012189:Retrospective Studies; D000093542:Gemcitabine
chemical_list: C520255:130-nm albumin-bound paclitaxel; D000418:Albumins; D000964:Antimetabolites, Antineoplastic; D003841:Deoxycytidine; D017239:Paclitaxel; D000093542:Gemcitabine